Bank Of America Corp Viking Therapeutics, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 430,782 shares of VKTX stock, worth $23.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

430,782

Previous 412,415 4.45%

Holding current value

$23.9 Million

Previous $33.8 Million 32.48%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $870,412 - $1.47 Million	18,367 Added 4.45%	430,782 $22.8 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $6.23 Million - $33.9 Million	-358,208 Reduced 46.48%	412,415 $33.8 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $3.38 Million - $7.19 Million	365,857 Added 90.39%	770,623 $14.3 Million
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $5.71 Million - $9.55 Million	-385,079 Reduced 48.75%	404,766 $6.56 Million
Q1 2023 May 12, 2023	BUY	$8.08 - $17.33 $5.6 Million - $12 Million	692,945 Added 715.11%	789,845 $13.2 Million
Q4 2022 Feb 10, 2023	SELL	$2.72 - $9.4 $56,793 - $196,272	-20,880 Reduced 17.73%	96,900 $910,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $3.89 $7,856 - $11,985	-3,081 Reduced 2.55%	117,780 $320,000
Q2 2022 Aug 12, 2022	BUY	$2.11 - $3.15 $148,328 - $221,438	70,298 Added 139.03%	120,861 $349,000
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $12,174 - $19,803	-4,058 Reduced 7.43%	50,563 $152,000
Q4 2021 Feb 08, 2022	SELL	$4.6 - $6.72 $1.09 Million - $1.6 Million	-237,961 Reduced 81.33%	54,621 $251,000
Q3 2021 Nov 15, 2021	BUY	$5.58 - $7.04 $82,801 - $104,466	14,839 Added 5.34%	292,582 $1.84 Million
Q2 2021 Sep 13, 2021	BUY	$5.19 - $6.73 $1.44 Million - $1.87 Million	277,743 New	277,743 $1.66 Million

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.25B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Viking Therapeutics, Inc. Transaction History